No photo of Victoria Meucci Villaflor

View Scopus Profile

Victoria Meucci Villaflor

  • 1544 Citations
20052020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Training Experience

2001Residency, Rush University Medical Center
2004Fellowship, Rush University Medical Center

Education/Academic qualification

MD, Rush Medical Collage

… → 1998

Fingerprint Dive into the research topics where Victoria Meucci Villaflor is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 15 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants

Prot #Ad-p53-002: A Phase 2, Multi-Center, Open Label Study to Evaluate Efficacy and Safety of Adenoviral p53 (Ad-p53) in Combination with Immune Checkpoint Inhibitor Therapy in Patients with Progression or Recurrence of Head and Neck Squamous Cell Carcin

Villaflor, V. M.

MultiVir Inc.

11/22/19 → 11/22/22

Project: Research project

Prot #BTCRC-HN17-111: Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-Positive Salivary Gland Carcinoma

Villaflor, V. M.

Hoosier Cancer Research Network, Inc., Merck Sharp & Dohme Corp.

10/9/19 → 10/9/22

Project: Research project

Prot #XB99016/NU 19L01: Phase Ib Study of Brigatinib Plus Bevacizumab in Patients with ALK-rearranged Non-Small Cell Lung Cancer (NSCLC) Who Have Previously Progressed on Prior ALK-Directed Therapy

Villaflor, V. M.

Millennium Pharmaceuticals, Inc

9/16/19 → 9/16/22

Project: Research project

Prot #WO40242: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of Atezolizumab (Anti-PD-L1 Antibody) As Adjuvant Therapy After Definitive Local Therapy In Patients With High-Risk Locally Advanced Squamous Cell Carcinoma Of Th

Villaflor, V. M.

Genentech, Inc.

8/21/19 → 8/21/22

Project: Research project

Prot #HCRN GI17-319/NU UNC19I02: A Single Arm, Multi-Center Phase 2 Trial of mFOLFOX6 + Trastuzumab + Avelumab in First-Line, Metastatic, HER2-Amplified Gastric and Esophageal Adenocarcinomas

Villaflor, V. M.

Hoosier Cancer Research Network, Inc., EMD Serono Research & Development Institute, Inc.

8/12/19 → 8/12/22

Project: Research project

Research Output

  • 1544 Citations
  • 41 Article
  • 8 Review article
  • 2 Chapter
  • 2 Comment/debate

Survivorship support in head and neck cancer: American Head and Neck Society survey

Cognetti, D. M., Villaflor, V. M., Fakhry, C., Miller, M. C. & Malloy, K. M., May 1 2020, In : Head and Neck. 42, 5, p. 939-944 6 p.

Research output: Contribution to journal › Article

    • Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti–PD-1/PD-L1 Therapy in Non–Small-Cell Lung Cancer

    Chae, Y. K., Davis, A. A., Raparia, K., Agte, S., Pan, A., Mohindra, N., Villaflor, V. & Giles, F., Mar 2019, In : Clinical Lung Cancer. 20, 2, p. 88-96.e6

    Research output: Contribution to journal › Article

    • 16 Scopus citations

    Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer

    Chae, Y. K., Viveiros, P., Lopes, G., Sukhadia, B., Sheikh, M. M., Saravia, D., Florou, V., Sokol, E. S., Frampton, G. M., Chalmers, Z. R., Ali, S. M., Ross, J. S., Chang, S., Wang, S., Chiec, L., Rahbari, A., Mohindra, N., Villaflor, V., Shin, S. H., Oh, M. & 5 others, Anker, J., Park, L. C., Wang, V., Chuang, J. & Park, W., Oct 2019, In : Journal of Thoracic Oncology. 14, 10, p. 1807-1817 11 p.

    Research output: Contribution to journal › Article

    • 1 Scopus citations

    Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer

    Chae, Y. K., Davis, A. A., Agte, S., Pan, A., Simon, N. I., Iams, W. T., Cruz, M. R., Tamragouri, K., Rhee, K., Mohindra, N., Villaflor, V., Park, W., Lopes, G. & Giles, F. J., Jun 2019, In : Oncologist. 24, 6, p. 820-828 9 p.

    Research output: Contribution to journal › Article

    • 11 Scopus citations

    Erratum: ERRATUM: OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer (Ann Oncol (2019) DOI: 10.1093/annonc/mdy522)

    Seiwert, T. Y., Foster, C. C., Blair, E. A., Karrison, T. G., Agrawal, N., Melotek, J. M., Portugal, L., Brisson, R. J., Dekker, A., Kochanny, S., Gooi, Z., Lingen, M. W., Villaflor, V. M., Ginat, D. T., Haraf, D. J. & Vokes, E. E., Oct 1 2019, In : Annals of Oncology. 30, 10, 1 p.

    Research output: Contribution to journal › Comment/debate

    Open Access
    • 5 Scopus citations